Link Cell Therapies Begins CAR-T Trial, Expands Series A to $90 Million

Link Cell Therapies has initiated clinical dosing of its lead logic-gated CAR-T therapy, LNK001, while expanding its Series A financing from $60 million to $90 million and adding senior executives to lead the oncology company through its next stage of clinical development. Cancer Focus Fund is among the new organizations financing Link’s Phase 1 study at MD Anderson Cancer Center in patients with advanced or metastatic clear cell renal cell carcinoma.